How Common Are Ezetimibe Side Effects Overall?
Ezetimibe, a cholesterol-lowering drug often sold as Zetia, has a low rate of side effects in clinical trials and real-world use. In monotherapy trials involving over 2,300 patients, about 4% discontinued due to adverse events, compared to 3.3% on placebo.[1] Common side effects (occurring in ≥2% of patients and more than placebo) include upper respiratory tract infection (4.3%), diarrhea (2.5%), and arthralgia (2.3%). Most are mild and resolve without stopping treatment.[1][2]
What Are the Most Frequent Side Effects?
- Gastrointestinal: Diarrhea (2-4%), abdominal pain (2-3%).
- Musculoskeletal: Joint pain (2-3%), back pain (2-4%).
- Respiratory: Sinusitis or upper respiratory infection (3-4%).
- Other: Fatigue (2%), headache (2%).[1][2]
These rates come from pivotal trials like the 48-week monotherapy study and pooled data from 1,195 patients.[1]
Side Effects When Combined with Statins
Ezetimibe is often paired with statins like simvastatin (Vytorin). In such combos, side effects mirror statin profiles but with slight increases:
- Muscle-related issues (myalgia): 3-5%, elevated liver enzymes: 0.5-1%.
- No significant rise in rhabdomyolysis risk.[1][3]
In the IMPROVE-IT trial (18,144 post-heart attack patients), serious adverse events were similar to simvastatin alone (34.4% vs. 34.2%).[3]
Rare but Serious Side Effects
Severe reactions occur in <1-2%:
- Liver: Elevated ALT/AST (0.5-2%), rare hepatitis.
- Muscle: Myopathy or rhabdomyolysis (<0.2%), higher if on fibrates.
- Allergic: Rash, angioedema (<1%).
- Other: Pancreatitis, thrombocytopenia (very rare).[1][2]
Post-marketing reports note gallbladder issues in <0.1%.[2]
How Do Real-World Rates Compare to Trials?
Patient reviews on Drugs.com show 38% report no side effects, 33% mild ones (e.g., stomach upset), and 29% moderate/severe (e.g., muscle pain).[4] FDA data from 2002-2023 logs ~15,000 adverse event reports, but most are non-serious and confounded by combo use.[5] Incidence drops with long-term use as patients tolerate it better.
Who’s at Higher Risk?
Older adults (>65), those with liver disease, or on multiple cholesterol drugs face elevated muscle/liver risks. Monitor with blood tests.[1] No major differences by gender or race in trials.[2]
[1]: Zetia Prescribing Information (FDA)
[2]: Ezetimibe Summary of Product Characteristics (EMA)
[3]: Cannon CP et al., N Engl J Med 2015; IMPROVE-IT Trial.
[4]: Drugs.com User Reviews for Ezetimibe
[5]: FDA FAERS Public Dashboard